Full-Time

Lead Maintenance Mechanic

Deadline 8/5/27
WuXi AppTec

WuXi AppTec

1,001-5,000 employees

Global contract research, development, manufacturing organization

No salary listed

Middletown, DE, USA

In Person

Category
General Maintenance & Repair (1)
Required Skills
Microsoft Office
HVAC
Inventory Management
GMP

Get referred to WuXi AppTec

See people who can refer or advise you

Requirements
  • High School Diploma or GED.
  • At least 3 years of hands-on maintenance experience in a pharmaceutical, biotechnology, or highly regulated industrial environment.
  • Strong mechanical and electrical troubleshooting skills involving pumps, motors, valves, air handling units, boilers, chillers, 480-volt three-phase distribution, and medium-voltage control logic.
  • Demonstrated understanding of working in cleanroom environments and following strict gowning and documentation protocols.
  • Familiarity with building control systems and interfacing equipment.
  • Basic proficiency with Microsoft Office and experience using a computerized maintenance management system.
  • Ability to clearly and professionally communicate technical issues to non-technical stakeholders in person and through electronic communications.
  • Ability to write technical subject matter for communications with engineering.
  • Ability to work in a plant environment with variable noise levels.
  • Ability to wear appropriate personal protective equipment, including respirators and cleanroom bunny suits.
  • Ability to stand, sit, and walk for long periods of time.
  • Ability to lift 50 pounds occasionally.
  • Ability to crouch, bend, twist, and reach in tight mechanical spaces.
  • Ability to climb ladders, stairs, and scaffolding to access rooftop equipment.
  • Ability to work in boiler rooms, refrigerated storage, and outdoors.
  • Clarity of vision and ability to identify and distinguish color-coded wiring and piping.
Responsibilities
  • Perform routine and corrective maintenance on utilities and facilities equipment, including boilers, deaerators, chillers, cooling towers, air compressors, process water systems, pumps, seals, exchangers, and generators.
  • Monitor and maintain water purification systems, clean steam generators, and heating, ventilation, and air-conditioning systems using building management and environmental monitoring systems.
  • Execute preventive and predictive maintenance tasks, including assisting with thermography, vibration analysis, data collection, and oil sampling.
  • Serve as the first responder for utility alarms and equipment failures.
  • Provide on-site escort and technical over-the-shoulder supervision for specialized vendors.
  • Execute permitting procedures and coordinate daily maintenance and operational tasks.
  • Complete computerized maintenance management system work orders with detailed documentation of parts used and tasks performed for regulatory compliance.
  • Maintain the physical organization of the utilities shop and spare-parts inventory, and identify and request restocking of critical components.
  • Participate in hazardous energy control procedures and the lockout/tagout program.
  • Execute safe-work permitting for contractors.
  • Assist maintenance management in identifying equipment trends or recurring failures and suggest mechanical or operational continuous improvements.
  • Identify and propose continuous improvements to equipment or workflows that enhance yield, reduce ergonomic strain, and decrease setup time.
  • Execute and review maintenance documentation in real time in compliance with attributable, legible, contemporaneous, original, and accurate documentation practices.
  • Capture and maintain accurate records of maintenance activities, work orders, standard operating procedures, calibration, and validation reports through the computerized maintenance management system.
  • Assist in executing qualification and validation protocols for new facilities and utilities equipment.
  • Support maintenance management during regulatory audits by retrieving logs and explaining maintenance histories.
  • Lead the drafting and periodic review of standard operating procedures and drawings to ensure alignment with current good manufacturing practices.
  • Maintain production suites in a constant state of inspection readiness for Food and Drug Administration, Drug Enforcement Administration, internal, and client-led quality audits.
  • Serve as a technical mentor to the expanding maintenance team and provide on-the-job training to junior personnel.
  • Collaborate daily with Production and Quality teams to align equipment availability with manufacturing needs.
  • Assist in drafting and red-lining standard operating procedures and as-built drawings.
  • Collaborate and coordinate with vendors for equipment-specific training.
  • Participate in executing change controls.
  • Identify opportunities for energy reduction and continuous improvement, such as identifying and repairing leaks, optimizing chiller sequences, and improving maintenance-operations sequences.
  • Participate in root cause analysis meetings to prevent recurrence of mechanical failures.
  • Support implementation of the computerized maintenance management system by providing accurate field data and feedback on system operability.
  • Provide technical subject matter expertise on equipment and consumables, address standardization, and identify cost-saving opportunities.
  • Support Environment, Health, and Safety through active participation in the Emergency Response Program.

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Get referred to WuXi AppTec

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • WuXi AppTec raised 2026 revenue guidance to RMB 58.5-60.5 billion on August 3, 2026.
  • H1 2026 revenue rose 38.9%, and backlog reached RMB 66.43 billion.
  • Delaware starts Q4 2026 and Singapore starts 2027, expanding non-China manufacturing capacity.

What critics are saying

  • On June 8, 2026, DoD added WuXi AppTec to the 1260H Chinese military list.
  • Customers terminated, paused, and redirected programs within weeks after the June 2026 designation.
  • If BIOSECURE targets WuXi in December 2026, U.S. business continuity faces existential damage.

What makes WuXi AppTec unique

  • WuXi AppTec’s integrated CRDMO spans discovery, development, and manufacturing across 30-plus countries.
  • Its 2026 capacity buildout covers Delaware, Singapore, Taixing, and Switzerland simultaneously.
  • DMPK compound management serves thousands of clients with one-million-plus compound storage and traceability.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 3rd, 2026
WuXi AppTec H1 revenue surges 39% to $4B, raises 2026 guidance amid US defence list inclusion

WuXi AppTec reported strong first-half 2026 results and raised its full-year guidance. The Chinese pharmaceutical contract research, development, and manufacturing organisation posted H1 revenue of RMB 28.90 billion, up 38.9% year-on-year, with continuing operations revenue rising 48.0%. Adjusted non-IFRS net profit increased 83.2% to RMB 11.57 billion, whilst the gross profit margin expanded 9.4 percentage points to 53.9%. The company's backlog for continuing operations grew 25.2% to RMB 66.43 billion as of 30 June 2026. WuXi AppTec raised its 2026 total revenue target to RMB 58.5–60.5 billion, up from RMB 51.3–53.0 billion previously. The firm also increased its capital expenditure guidance to RMB 7.5–8.5 billion to support accelerated global capacity expansion. The company addressed its inclusion on the US Department of Defence's 1260H list, calling it erroneous and confirming legal action to protect stakeholder interests.

Associated Press
Jul 7th, 2026
WuXi AppTec launches automated compound management system with fourfold storage density and full traceability

WuXi AppTec DMPK has launched an automated compound management platform serving thousands of pharmaceutical and biotechnology companies worldwide, with storage capacity exceeding one million compounds. The system provides full lifecycle management through digital operations, featuring automated robotic retrieval, real-time weighing data integration with high-precision balances, and automated preparation via Hamilton systems. The platform addresses three major challenges in drug metabolism and pharmacokinetics research: diverse container types, large compound libraries, and strict storage requirements. Key capabilities include real-time logistics tracking, image recognition-based automated picking, and high-density mobile storage delivering approximately fourfold capacity versus fixed-cabinet layouts. The system maintains tamper-proof audit logs and role-based access control whilst integrating with the Mosaic Compound Management System. WuXi AppTec DMPK offers flexible managed services covering sample receipt, secure storage, distribution, and disposal, aiming to reduce operational costs and accelerate research timelines.

Associated Press
Jun 11th, 2026
WuXi AppTec expands peptide and oligonucleotide capacity, eyes 40% revenue growth in 2026

WuXi AppTec is expanding its global manufacturing capabilities for emerging drug modalities including peptides, oligonucleotides and targeted protein degraders, according to Pharma Manufacturing. The company's WuXi TIDES platform, focused on oligonucleotides and peptides, is projected to achieve approximately 40% year-on-year revenue growth in 2026. The company's solid-phase peptide synthesis reactor volume exceeded 100,000 litres at end-2025 and is expected to reach 130,000 litres by end-2026. New production facilities are under construction in Taixing, China, scheduled for 2027 operation, and Singapore, planned for 2028. WuXi AppTec is investing in process technologies combining solid-phase and liquid-phase synthesis to improve scalability for complex molecules. The company is also developing integrated approaches for antibody-drug conjugates and targeted protein degraders, incorporating earlier-stage chemistry and biology integration.

Yahoo Finance
Jun 9th, 2026
WuXi AppTec added to Pentagon's Chinese military list, vows to challenge 'erroneous designation

WuXi AppTec has been added to the Pentagon's list of "Chinese military companies", escalating tensions between the pharmaceutical manufacturer and the US. The Department of Defence updated its Section 1260H list on 8 June, adding WuXi alongside other Chinese firms including BYD and Comac. The DoD claims WuXi has links to China's State Administration for Science, Technology and Industry for National Defence and the People's Liberation Army. WuXi strongly denied the designation, calling it "clearly a mistake" and stating it is not owned, controlled or affiliated with any Chinese military or government entity. The contract research and manufacturing organisation, which operates in over 30 countries, reported revenues of $1.83 billion in Q1 2026, up 39.4% year-over-year. WuXi was previously removed from the BIOSECURE Act in October 2025.

Associated Press
Jun 5th, 2026
WuXi AppTec boosts capex 17% to $77M-$89M for global manufacturing expansion

WuXi AppTec is accelerating global manufacturing expansion across the United States, Europe and Asia, increasing capital expenditures by at least 17% this year to between RMB 6.5 billion and RMB 7.5 billion. The pharmaceutical contract research, development and manufacturing organisation is responding to growing customer demand, particularly for peptides and oligonucleotides. The company's new Middletown, Delaware facility will begin oral solid dosage manufacturing in Q4 2026, becoming its largest US site at 1.74 million square feet. In Europe, WuXi is expanding its Couvert, Switzerland site, whilst a Singapore facility is expected to begin Phase I operations in 2027. WuXi AppTec's small molecule pipeline reached 3,550 molecules by end-March 2026. Its TIDES business is projected to grow approximately 40% year-over-year.